Additionally, ARHGAP9 was supposed to be a useful marker for the treatment of bladder cancer as its downregulated was correlated with bladder prognosis, and the study found a nearly 3-fold increased risk of cancer-specific death when ARHGAP9 levels were reduced [22]. The gene discussed is ARHGAP9; the disease is urogenital neoplasm.